Antacor is the trade name for the oral hypoglycemic agent dagliflozin, which is beneficial for the treatment of heart failure patients with reduced ejection fraction scores. Dagliflozin, a sodium-glucose cotransporter protein 2 inhibitor, is a novel oral hypoglycemic agent whose indication was expanded by the FDA on May 5, 2020, for the treatment of heart failure with reduced ejection fraction to reduce the risk of death and hospitalization in heart failure patients. The cardiovascular benefits of dagliflozin are mainly focused on: improving the energy metabolism of cardiomyocytes; sodium drainage diuretic effect, reducing the preload of the heart heart; animal experimental studies have shown that dagliflozin can inhibit myocardial fibrosis and improve myocardial remodeling to achieve the role of cardioprotection. Dagliflozin in heart failure patients and diabetic patients, its adverse reactions are: hypoglycemia, hypovolemia, ketoacidosis, genital fungal infections and so on. Dagliflozin is mainly excreted by the kidneys and is contraindicated in dialysis patients and patients with severe renal insufficiency without cardiovascular disease. If you need to use the drug, it should be used rationally under the guidance of a physician to avoid adverse reactions from self-use.